This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insights Into Bausch (BHC) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Bausch (BHC) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch (BHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Bausch (BHC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Value Stocks to Buy for February 7th
by Zacks Equity Research
MITSY, JSAIY and BHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 7, 2023.
UnitedHealth Group's (UNH) Brazil Unit Draws Buyout Interests
by Zacks Equity Research
UnitedHealth Group (UNH) expects to divest its troubled Brazil business, enhancing its overall results.
Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal
by Zacks Equity Research
Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
by Zacks Equity Research
Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year.
UnitedHealth Group's (UNH) Arm Launches OptumRx Weight Engage
by Zacks Equity Research
UnitedHealth Group (UNH) enhances Optum Rx's offerings with the launch of the Weight Engage program.
Implied Volatility Surging for On Bausch Health Companies (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch Health Companies (BHC) stock based on the movements in the options market lately.
UnitedHealth (UNH) Unit Awarded a Medicaid Contract by AHCCCS
by Zacks Equity Research
UnitedHealth Group's (UNH) unit has been picked up by AHCCCS to serve members of the ALTCS EPD program, which will serve as a means to further expand the health insurer's statewide footprint.
Wall Street Analysts Think Bausch (BHC) Could Surge 30.14%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Bausch (BHC) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bausch Health (BHC) and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have performed compared to their sector so far this year.
Wall Street Analysts Believe Bausch (BHC) Could Rally 38.28%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38.3% in Bausch (BHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Encompass Health (EHC) Opens Hospital to Boost Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.
Has Aveanna Healthcare (AVAH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Bausch Health (BHC) have performed compared to their sector so far this year.
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
by Zacks Equity Research
Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.
UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail
by Zacks Equity Research
UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.
Bausch (BHC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Bausch (BHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
by Zacks Equity Research
TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.
Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated
by Zacks Equity Research
Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.
Bausch (BHC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.